MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design.
Weijing CaiDapeng ZhouWeibo WuWen Ling TanJiaqian WangCaicun ZhouYanyan LouPublished in: BMC genomics (2018)
Our results support the feasibility of discovering individualized HLA Class II presented mutant peptides as candidates for immunodiagnosis and immunotherapy of lung adenocarcinoma.